Biohaven Pharmaceutical in a presentation at today’s Wells Fargo Healthcare Conference included an update on the new drug application filing acceptance and PDUFA date for rimegepant ODT. The FDA informed the company that it has no current plans to hold an Advisory Committee, with filing acceptance and action date planned for in Q1 of 2020, Biohaven said in presentation slides. Further, preliminary evaluation of the application by the FDA did not identify any potential review issues at this time, Biohaven added. The stock is up 7%, or $2.69, to $40.80 in morning trading.